Moving forward, it is crucial to standardize pSMAD2 assessment methods and to expand analyses to larger HER2+ and Triple-negative cohorts of early-stage breast cancer to fully decipher subtype-specific roles of TGF-β signaling. Here, ERBB2 is linked to breast cancer.